X-Nico

2 unusual facts about atypical Chronic Myeloid Leukemia


Atypical chronic myeloid leukemia

This sharply contrasts with the outcome for CML, for which the prognosis was dramatically improved by the development of imatinib as a specific inhibitor of the BCR-ABL protein and in particular for CML.

In 2012 SETBP1 was identified as a novel oncogene in aCML; specific somatic mutations of this gene were discovered in patients affected by atypical Chronic Myeloid Leukemia (aCML) and related diseases.


Carlo Gambacorti-Passerini

In 2012 Dr. Gambacorti-Passerini discovered SETBP1 as a novel oncogene and identified specific mutations of this gene in patients affected by atypical Chronic Myeloid Leukemia (aCML).


see also